Health-related quality of life of multiple myeloma patients after the first-line treatment: results of a prospective cohort study

• Main Author: Drummond, Paula Lana de Miranda
• Publication Date: 2022
• Other Authors: Santos, Roberta Márcia Marques dos, Reis, Adriano Max Moreira, Malta, Jéssica Soares, Silveira, Lívia Pena, Costa, Iwyson Henrique Fernandes da, Marques, Bárbara Soares Diniz, Silva, Roberta Oliveira de Paula e, Fagundes, Evandro Maranhão, Colosimo, Enrico Antônio, Pádua, Cristiane Aparecida Menezes de
• Format: Article
• Language: eng
• Source: Research, Society and Development
• Download full: https://rsdjournal.org/index.php/rsd/article/view/34709
• topic: Mieloma Múltiple; Calidad de Vida; Talidomida; Bortezomib; Enfermedades del Sistema Nervioso Periférico.; Mieloma múltiplo; Qualidade de vida; Talidomida; Bortezomibe; Neuropatias periféricas.; Multiple Myeloma; Quality of life; Thalidomide; Bortezomib; Peripheral neuropathy.

Objective: The aim of this study was to evaluate whether there was an improvement or a deterioration of health-related quality of life (HRQoL) of multiple myeloma patients (MM), and to assess the associated factors with HRQoL after 12 months of treatment. Methods: We performed a prospective cohort study with MM patients in first-line treatment from public and private onco-hematology health services in a Brazilian metropolis. HRQoL, socio-demographic and clinical variables were obtained by interviews and review of medical charts. HRQoL and peripheral neuropathy (PN) were collected through validated instruments (QLQ-C30, QLQ-MY20, CINQ). Medians of the HRQoL scores, obtained at baseline and follow-up interviews, were compared. Median HRQOL scores at follow-up were compared by variables. The improvement or deterioration in HRQoL and the association with variables were measured. Results: Thirty-three patients completed the follow-up, with ISS III (25.0 %), on polypharmacy (72.2 %), using a thalidomide+bortezomib-based regimen as first-line (19.4 %), and median age of 66.5 years. HRQoL Summary score, Functioning, Symptom scales, and Future Perspective scores were improved between periods (p<0.05). Patients who were on polypharmacy, with severe PN, and with ISS III had deterioration in HRQoL; younger patients had improvement and older patients had deterioration in HRQoL (p<0.05). Conclusions: Our study showed that first-line treatment improved HRQoL of patients in the following QLQ-C30 scales: Summary score, Role functioning, Emotional functioning, Fatigue, Pain, and Constipation; and in QLQ-MY20, Future perspective was improved. Our study shows the importance of using patient-reported outcomes during MM treatment.